Research
Hormonal
The combination of cagrilintide and semaglutide (cagrANDsema) reduced weight by -14.13 kg compared to placebo.
CagrANDsema is an effective treatment option for weight loss in individuals with obesity.
StrongSupportsmedium confidence
Compared to placebo, cagrANDsema reduced weight by - 14.13 kg (95% CI: -16.49, -11.73).
Why this rating
Based on a systematic review and meta-analysis of RCTs.
Source
Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis
Hong Li et al. · Biomedicine & Pharmacotherapy · 2024
Meta-analysisCited 26×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →